- Home
- CGBD vs FTH Comparison
CGBD vs FTH Comparison
Compare CGBD & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CGBD | FTH |
|---|---|---|
| Founded | 2012 | 1999 |
| Country | United States | United States |
| Employees | 2500 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 741.0M | 835.7M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CGBD | FTH |
|---|---|---|
| Price | $10.77 | $28.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $12.50 | ★ $56.67 |
| AVG Volume (30 Days) | 297.5K | ★ 317.4K |
| Earning Date | 11-03-2026 | 11-13-2026 |
| Dividend Yield | ★ 15.44% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.95 | $17.50 |
| 52 Week High | $13.28 | $42.14 |
Technical Indicators
Market Signals| Indicator | CGBD | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 35.57 | 40.84 |
| Support Level | $10.53 | $23.47 |
| Resistance Level | $10.79 | $31.61 |
| Average True Range (ATR) | 0.22 | 2.42 |
| MACD | -0.10 | -0.88 |
| Stochastic Oscillator | 9.05 | 18.75 |
Price Performance
Historical ComparisonAbout CGBD Carlyle Secured Lending Inc.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.
About FTH Faeth Therapeutics Inc. Common Stock
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.